Author: Ravi Shankar

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United States District Court for the District of Columbia, principally challenging FDA’s alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom’s new drug application (NDA) for VOQUEZNA®. In the suit, BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom’s New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets. Phathom is evaluating the BDR filings, but believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom intends to take appropriate action to protect its statutory exclusivities.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: Phathom’s belief that FDA correctly evaluated and recognized the GAIN Act extension of the NCE exclusivity for VOQUEZNA tablets; Phathom’s intent to take appropriate actions to protect its statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; and the potential timing and outcome of the litigation filed by BDR. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: BDR may succeed in its challenge to FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets which would result in a reduction in the period of regulatory exclusivity and permit FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation, or public perception of them, may hurt Phathom’s stock price, VOQUEZNA sales, or Phathom’s business, financial condition and prospects; Phathom may not be able to obtain and maintain intellectual property protection, including patent term extensions, and may not be able to maintain non-patent regulatory exclusivity for VOQUEZNA for the time periods it expects or at all; Phathom may be unsuccessful in defending its Orange Book-listed patents against challenges by third parties; Phathom may face competition earlier than expected if it loses any of regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR litigation; and other risks described in Phathom’s prior press releases and filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to revise or update such statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses

88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment

Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations

Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027

Company to host a conference call and webcast today at 8:00 am ET featuring Dr. Joshua Sabari

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented potential best-in-class data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO Congress 2026 and announced plans to advance enozertinib into a global Phase 3 trial.

“These enozertinib systemic and intracranial response data set a new benchmark in 1L EGFR atypical NSCLC,” said Pratik S. Multani, M.D., chief medical officer. “The data are particularly impressive given that nearly two-thirds of our patients had baseline brain metastases, which is more than double the rate seen in competitor datasets, and which has historically been associated with poorer outcomes.”

“Supported by these potential best-in-class data and having successfully completed End-of-Phase 1 interactions with FDA, we are rapidly advancing enozertinib into a global Phase 3 registrational trial,” said Jacob M. Chacko, M.D., president and chief executive officer. “With rinzimetostat’s first Phase 3 trial in prostate cancer initiated earlier this year and enozertinib’s first Phase 3 trial in lung cancer planned for 1H 2027, ORIC has become a diversified, late-stage oncology company with two programs offering opportunities for broader development across indications with significant unmet need and meaningful commercial potential.”

Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC
Enozertinib is being evaluated in an ongoing Phase 1b trial in patients with locally advanced or metastatic NSCLC with EGFR atypical and EGFR exon 20 insertion mutations. Notably, enrollment allows patients with previously untreated brain metastases (i.e., active, untreated brain metastases). Key objectives of the trial included safety and determination of the recommended Phase 2 dose, along with assessment of antitumor activity based on investigator-assessed objective response rate (ORR), blinded independent central review (BICR)-assessed ORR, CNS-ORR according to modified RECIST 1.1 and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM), as well as DOR and PFS.

As of the September 4, 2026 cutoff date, data are presented for 26 patients who were treated with 80 mg once daily oral enozertinib, including 23 patients with P-loop and alpha C-helix compressing (PACC) mutations and 3 patients with L861Q mutations without a co-occurring PACC mutation. Brain metastases were present in 65% of patients at baseline, which is more than double the rate versus competitor datasets. Notably, 46% of all patients had previously untreated brain metastases.

Safety Analysis
Enozertinib was well tolerated with predominantly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities. Most frequent TRAEs included diarrhea, paronychia, and dermatitis acneiform. Six patients (23%) experienced Grade 3 TRAEs, all of which were resolved with dose modifications. There were no Grade 4 or 5 TRAEs and no treatment discontinuations related to TRAEs.

Meaningful Systemic Antitumor Activity
Tumor reductions were observed across all response-evaluable patients¹. Reductions were also observed across a wide range of mutations, including the most prevalent PACC mutations (e.g., G719X, S768I), a broad spectrum of PACC complex mutations, and L861Q mutations. Enozertinib demonstrated meaningful systemic activity, including:

• 84% (21 of 25) confirmed systemic ORR by investigator.
• 80% (20 of 25) confirmed systemic ORR by BICR.

Deep EGFR-mutant ctDNA molecular responses were achieved by Cycle 3 Day 1 in all response-evaluable patients across diverse mutations²:

• 100% of patients achieved MR90, defined as a ≥90% EGFR-mutant ctDNA reduction.
• 82% of patients achieved full clearance, which has been associated with improved long-term survival outcomes in prior Phase 3 NSCLC trials.

Compelling Intracranial Antitumor Activity
Enozertinib continues to demonstrate potential best-in-class intracranial efficacy. Notably, no new CNS lesions were observed in patients with or without baseline CNS metastases.

All response-evaluable patients with measurable CNS disease (90% without prior treatment for their CNS metastases) achieved CNS tumor reductions per investigator-assessment³. Enozertinib demonstrated compelling intracranial activity, including:

• 70% confirmed intracranial ORR by investigator.

Intracranial efficacy was also evaluated utilizing the more stringent BICR RANO-BM assessment criteria. Based on this assessment, CNS tumor reductions were observed in nearly all response-evaluable patients, including in patients with previously untreated CNS metastases⁴. Enozertinib demonstrated compelling intracranial activity, including:

• 67% (10 of 15) intracranial ORR by BICR RANO-BM.
• 40% (6 of 15) intracranial complete response rate by BICR RANO-BM, including in three patients with non-measurable CNS disease.

Promising Early Durability
Median progression-free survival and median duration of response data are immature. The Kaplan-Meier 6-month landmark PFS is 88%. Follow-up is ongoing with the majority of patients continuing on treatment.

Redwood-1 Phase 3 Initiation
Supported by potential best-in-class data presented at ESMO Congress 2026 and based on End-of-Phase 1 interactions with the FDA, ORIC plans to initiate Redwood-1, a global Phase 3 registrational trial in EGFR atypical NSCLC in 1H 2027. This trial plans to enroll approximately 360 patients with PACC and L861X mutations, including those with untreated brain metastases, randomized to receive 80 mg once daily oral enozertinib or physician’s choice of osimertinib or afatinib. Dual primary endpoints include ORR by BICR for potential accelerated approval as well as PFS by BICR for full approval. Key secondary endpoints include overall survival and intracranial ORR by BICR RANO-BM.

Poster Details
Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations
Presentation Number: 2627P
Session Date & Time: Monday, October 26, 2026; 12:00 – 12:45 p.m. CET
Session Title: Metastatic NSCLC
The poster presentation can be found on the ESMO Congress website here, and in the publication section of ORIC’s website here.

Conference Call and Webcast Details
The conference call and webcast will take place on Friday, October 23, 2026, at 8:00 a.m. ET. ORIC leadership plans to have Dr. Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine, join the call to share his perspective on the enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and an audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

__________________
¹ n=25 patients with opportunity for two post-baseline tumor assessments.
² n=22 patients with EGFR mutation in baseline plasma and opportunity for two post-baseline systemic tumor assessments. September 15, 2026 cutoff.
³ n=10 patients with measurable target CNS lesions per investigator assessment.
⁴ n=15 patients with baseline CNS metastases per BICR assessment.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of enozertinib; the potential advantages of enozertinib; statements regarding the potential best-in-class profile of enozertinib; clinical outcomes from studies of enozertinib, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for rinzimetostat and enozertinib, including the expected initiation of the Redwood-1 trial; plans underlying ORIC’s clinical trials and development; and statements by the company’s chief medical officer and chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as a clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness

Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition

Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced preclinical and translational data from an ePoster presentation at ESMO Congress 2026 highlighting the potential of rinzimetostat to enhance sensitivity to androgen receptor inhibition in prostate cancer.

“These results strengthen the rationale for combining PRC2 inhibition with androgen receptor targeted therapies across castration-sensitive and castration-resistant prostate cancer by limiting tumor adaptability and enhancing sensitivity to AR inhibition,” said Lori Friedman, PhD, chief scientific officer. “Verification of our preclinical results in patient samples, together with the potential advantages of targeting PRC2 via EED, reinforce our confidence in rinzimetostat’s potential best-in-class profile and support its evaluation across the prostate cancer disease spectrum, including in our ongoing Himalayas-1 Phase 3 trial.”

Rinzimetostat, a Next Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples from Patients with mCRPC

ePoster Number: 1128eP
Session Title: Developmental Therapeutics
Key findings of the presentation:

• Preclinical results suggest potential advantages of targeting PRC2 via EED with rinzimetostat over targeting EZH2:
  • Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.
  • No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.
  • Comparative preclinical studies demonstrated drug properties supporting rinzimetostat’s potential best-in-class profile, including favorable solubility, oral bioavailability, half-life and CYP profile.
• Rinzimetostat restored access to AR binding motifs and restricted accessibility at sites associated with lineage plasticity in preclinical prostate cancer models, supporting a mechanism that reinforces AR dependence and limits tumor adaptation.
  • Rinzimetostat synergized with AR inhibition in preclinical prostate cancer studies.
  • KLK2 and STEAP1 luminal markers increased following rinzimetostat treatment in preclinical studies.
• Samples from patients with mCRPC treated with single-agent rinzimetostat demonstrated biological changes consistent with the preclinical findings:
  • Plasma cfDNA methylation profiling showed epigenetic shifts indicative of increased AR signaling after one treatment cycle in most patients assessed.
  • Paired tumor biopsies showed increased levels of luminal and AR-associated markers PSMA and KLK2.

The ePoster presentation can be found on the ESMO Congress website here, and in the publication section of ORIC’s website here.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat; the potential advantages of rinzimetostat, including by targeting PRC2 via EED instead of EZH2; statements regarding the potential best-in-class profile of rinzimetostat; the development plans and timelines for rinzimetostat; plans underlying ORIC’s clinical trials and development; and statements by the company’s chief scientific officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — On October 21, Professor Joseph Sifakis, a Turing Award laureate and Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center, visited the center for in-depth discussions with CaoCao’s technology team. On the same day, CaoCao launched a research project on Trustworthy Decision-Making and Multi-Agent Coordination for Robotaxi Curbside Operations. Professor Sifakis witnessed the launch and offered valuable recommendations based on his extensive research experience.

Professor Sifakis is one of the pioneers of model checking. He received the 2007 Turing Award for his contributions to the development of model-checking theory and its applications. He has long been engaged in research on complex intelligent systems and Trustworthy Autonomous Systems, areas closely related to the safety and trustworthiness challenges facing Robotaxi operations at scale.

In June this year, Professor Sifakis was formally invited to serve as Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center to provide academic guidance for CaoCao’s AI transformation and the development of its autonomous driving technologies. At the 2026 World Artificial Intelligence Conference, he outlined three fundamental principles for trustworthy Robotaxis: Safe by Design, System Coordination, and Runtime Assurance. He also noted that CaoCao’s RoboX ecosystem closely aligns with the systems-engineering principles underlying Trustworthy Autonomous Systems.

Passenger pick-up and drop-off are critical to the Robotaxi experience. This newly launched research project focuses on safety and trustworthiness in this everyday mobility scenario, exploring how the theory of Trustworthy Autonomous Systems can be translated into verifiable engineering methods.

Drawing on 11 years of real-world operating data and experience from CaoCao’s mobility services, the project will examine the conditions under which curbside stopping locations can be used, passenger boarding and alighting paths, vehicle stopping behavior, and system coordination. By exploring methods for cross-validating results from simulation and real-vehicle testing, the project aims to build a body of reusable, scenario-based evidence to support safety validation for the trustworthy transfer of Robotaxi operations across cities and their deployment worldwide.

Contact:
Jing Liu   
Jing.Liu3@caocaoglobal.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/66d7d57d-af7c-4812-91ed-15420008c24e

The shareholders are invited to attend the general meeting of Econocom Group SE, with registered office at Place du Champ de Mars 5, 1050 Brussels, Belgium, registered with the Crossroads Bank for Enterprises under number 0422.646.816 (the “Company“), to be held on Tuesday 24 November 2026 at 2 p.m. (Belgian time) at the Company’s registered office (the “Meeting“).

AGENDA AND PROPOSED RESOLUTIONS FOR THE GENERAL MEETING

1. Appointment of Ms. Véronique Torner as independent director

Proposed resolution:
Proposal to appoint Ms. Véronique Torner as independent director of the Company for a term of 4 (four) years, with immediate effect and ending at the close of the annual general meeting to be held in 2030.

Ms. Véronique Torner meets the independence criteria set out in Article 7:87 of the Code on companies and associations and Article 3.5 of the 2020 Belgian Code on corporate governance. Pursuant to Article 7:87, § 1, paragraph 3 of the Code on companies and associations, the board of directors expressly confirms that there is no element liable to compromise her independence with regard to the criteria mentioned above.

2. Powers of attorney

Proposed resolution:
Proposal to grant powers of attorney to (i) the executive directors and the managing directors of Econocom Group SE, with the possibility of substitution, for the execution of the aforementioned resolutions and in order to proceed with publication and other formalities, and (ii) to Mr. Jérôme Lehmann (employee of Econocom group) and/or Ms. Nikita Tissot and/or Ms. Marie Florival (NautaDutilh BV/SRL), with the power of substitution, in order to proceed with the filing and publication formalities.

FORMALITIES FOR PARTICIPATING IN GENERAL MEETING

In order to attend the Meeting of 24 November 2026, shareholders are requested to comply with Articles 28 and 29 of the Company’s Articles of Association and the following formalities.

1. Record date

The record date is 10 November 2026 at midnight (Belgian time). Only persons registered as shareholders on that date and at that time will be authorised to attend and vote at the Meeting. The number of shares held on the date of the Meeting is not relevant.

Holders of registered shares must be recorded in the Company’s register of registered shares register by 10 November 2026 at midnight. (Belgian time).

Holders of dematerialized shares must be recorded as shareholders with an authorised account holder or Euroclear Belgium on 10 November 2026 at midnight. (Belgian time).

2. Intent to attend the Meeting

Shareholders must inform the board of directors, by e-mail sent to generalsecretariat@econocom.com – or, for holders of dematerialised shares, to the email address ebe.issuer@euroclear.com – or by registered letter, by 18 November 2026 at the latest, of their intention to attend the Meeting, indicating the number of shares they intend to vote. In addition, the holders of dematerialized shares must prove their registration as shareholders on the record date.

In order to attend the Meeting, shareholders and proxyholders must, in addition to the formalities set out in the previous paragraph, prove their identity, and, where applicable, their power of attorney, at the latest immediately before the start of the meeting.

3. Vote by proxy or by letter

Shareholders may exercise their voting rights prior to the Meeting either (i) by voting remotely by correspondence, or (ii) by giving a proxy to a person designated by the board of directors.

In the event of a proxy vote, the proxy holder will automatically be a representative of the Company (or one of its subsidiaries) which will be designated for this purpose.

This proxy holder will only exercise the voting right in accordance with the voting instructions contained in the proxy form.

Proxy voting and postal voting forms approved by the Company must be used for this purpose. They can be downloaded from the website https://www.econocom.com/en/investors/general-meetings.

In addition to the above-mentioned formalities, shareholders must send duly completed and signed proxy voting and postal voting forms to the e-mail address generalsecretariat@econocom.com – or for holders of dematerialized shares to the e-mail address ebe.issuer@euroclear.com – by 18 November 2026 at the latest.

Shareholders are kindly asked to promote the sending by e-mail of a scanned or photographed copy of the proxy or postal voting form and to subsequently send the originals by post to the Company’s registered office.

It is recalled, moreover, that proxy and postal voting forms may also be signed by an electronic signature process as provided for in Article 7:143 § 2 of the Code on companies and associations.

4. New agenda items, proposed resolutions and the right to ask questions

Shareholders holding at least 3% of the capital wishing to request the addition of new items on the agenda or to submit new proposals for resolutions must, in addition to the aforementioned formalities, prove that they hold the required percentage of shares on the date of their request and submit their request to the Company’s registered office or by email to generalsecretariat@econocom.com by 2 November 2026, at the latest.

As the case may be, the amended agenda will be published no later than 9 November 2026.

Shareholders who wish to submit questions prior to the Meeting and who respected the aforementioned formalities, are invited to send them, by 18 November 2026 at the latest, preferably to the email address generalsecretariat@econocom.com, or by post to the following address : Leuvensesteenweg 510/B80, 1930 Zaventem.

5. Bondholders and holders of subscription rights

Bondholders and holders of subscription rights issued by the Company may attend the Meeting in advisory capacity only (i.e. without voting rights). To do so, they must inform the board of directors by email at generalsecretariat@econocom.com by 18 November 2026, at the latest, of their intention to participate in the Meeting.

6. Documents

The documents to be provided to the Meeting, the agenda, as possibly amended, and the forms to vote by proxy or by letter, as possibly amended, shall be available as from the publication of this notice on the Company’s website (https://www.econocom.com/en/investors/general-meetings) and at the Company’s registered office.

The aforementioned formalities and the instructions set out on the Company’s website and on the forms to vote by proxy or by letter must be strictly complied with.

Yours faithfully,

On behalf of the board of directors,

Update on the Share Buyback Program and the Liquidity Agreement

Period from 15 October 2026 to 21 October 2026

Share Buyback Program
On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased.

Bekaert announces today that during the period from 15 October 2026 to 21 October 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 41 000 shares.

The table below provides an overview of the transactions under the Program during the period from 15 October 2026 to 21 October 2026:

	Repurchase of shares
Date	Market	Number of Shares	Average Price paid (€)	Highest Price paid (€)	Lowest Price paid (€)	Total Amount (€)
15 October 2026	Euronext Brussels	5 500	39.32	39.60	38.95	216 260
	MTF CBOE	3 000	39.33	39.60	39.05	117 990
	MTF Turquoise
	MTF Aquis
16 October 2026	Euronext Brussels	4 072	39.80	39.95	39.50	162 066
	MTF CBOE	3 928	39.80	39.95	39.50	156 334
	MTF Turquoise
	MTF Aquis
19 October 2026	Euronext Brussels	5 351	39.24	39.50	39.10	209 973
	MTF CBOE	3 149	39.24	39.50	39.10	123 567
	MTF Turquoise
	MTF Aquis
20 October 2026	Euronext Brussels	4 545	39.32	39.60	38.85	178 709
	MTF CBOE	3 955	39.31	39.55	39.00	155 471
	MTF Turquoise
	MTF Aquis
21 October 2026	Euronext Brussels	3 968	40.71	41.65	39.20	161 537
	MTF CBOE	3 532	40.77	41.65	39.20	144 000
	MTF Turquoise
	MTF Aquis
Total		41 000	39.66	41.65	38.85	1 625 907

Liquidity agreement
In relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 25 June 2024, Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 805 shares during the period from 15 October 2026 to 21 October 2026 on Euronext Brussels. During the same period, Kepler Cheuvreux on behalf of Bekaert has sold 4 400 shares on Euronext Brussels.

The tables below provide an overview of the transactions under the liquidity agreement during the period from 15 October 2026 to 21 October 2026:

	Purchase of shares
Date	Number of Shares	Average Price (€)	Highest Price (€)	Lowest Price (€)	Total Amount (€)
15 October 2026	1 000	39.26	39.60	39.00	39 260
16 October 2026	0	0.00	0.00	0.00	0
19 October 2026	1 200	39.28	39.60	39.10	47 136
20 October 2026	600	38.80	38.80	38.80	23 280
21 October 2026	5	39.00	39.00	39.00	195
Total	2 805				109 871

	Sale of shares
Date	Number of Shares	Average Price (€)	Highest Price (€)	Lowest Price (€)	Total Amount (€)
15 October 2026	0	0.00	0.00	0.00	0
16 October 2026	1 200	39.72	40.00	39.50	47 664
19 October 2026	0	0.00	0.00	0.00	0
20 October 2026	400	39.40	39.50	39.30	15 760
21 October 2026	2 800	40.38	41.40	39.20	113 064
Total	4 400				176 488

The balance held by Bekaert under the liquidity agreement at the end of the period is 23 471 shares.

On 21 October 2026 after closing of the market, Bekaert holds 1 795 100 own shares, or 3.63% of the total number of the outstanding shares.

This information is also made available on the investor relations pages of our website.

Attachment

• p261023E – Bekaert – Update on the Share Buyback Program and the Liquidity Agreement

Bank of Åland Plc
Interim Report
October 23, 2026 9.00 EEST

Interim Report for the period January – September 2026

Continued solid development in the core business

“Our business continues to perform well, and we generated a return on equity of 16.9 per cent during the quarter.

“The volume of actively managed assets that we manage on behalf of our customers contin­ued to record strong net inflows and reached a new all-time high of EUR 12.5 billion. Our three main segments, Private Banking, Premium Banking and IT, together improved their results compared with the corresponding period last year.

“We received confirmation of our strong customer relationships in EPSI Rating’s customer sur­vey of the Finnish banking and finance sector, in which the Bank of Åland received the sector’s highest ratings for service, quality, customer loyalty, trust and sustainability.

“We see that our way of serving customers in our segments continues to be appreciated. During the quarter, we therefore began establishing operations in Haparanda and Luleå. This initiative is a natural step in our continued growth in Sweden and builds on the Bank of Åland’s long experience as a full-service bank in both Finland and Sweden, as well as our understand­ing of the needs that arise when people and businesses live and operate across national borders.

“Despite the continued uncertainty in the world around us, we see good opportunities to con­tinue developing our business in the near future.”

Peter Wiklöf
Managing Director and Chief Executive

January−September 2026 compared to January−September 2025

• Net operating profit decreased by 11 per cent and amounted to EUR 45.6 M (51.0).
• Core income in the form of net interest income, net commission income and IT income increased by 2 per cent to EUR 162.0 M (159.1).
• Other income decreased by 69 per cent to EUR 1.5 M (4.8).
• Total expenses increased by 5 per cent to EUR 117.9 M (112.3).
• Net impairment losses on financial assets (including recoveries) amoun­ted to a net recovery of EUR 0.0 M (net impairment losses of 0.6), equiva­lent to a loan loss level of 0.00 per cent (0.02).
• Return on equity after taxes (ROE) decreased to 15.8 per cent (18.4).
• Earnings per share decreased by 13 per cent to EUR 2.36 (2.71).
• The common equity Tier 1 capital ratio decreased to 12.4 per cent (12.7 on December 31, 2025).
• Unchanged future outlook: The Bank of Åland expects its return on equity after taxes (ROE) to continue to exceed its long-term financial target of 15 per cent during 2026.

The third quarter of 2026 compared to the third quarter 2025

• Net operating profit decreased by 4 per cent and amounted to EUR 15.8 M (16.3).
• Core income in the form of net interest income, net commission income and IT income increased by 2 per cent to EUR 52.4 M (51.1).
• Other income increased by 51 per cent to EUR 1.3 M (0.8).
• Total expenses increased by 5 per cent to EUR 37.7 M (35.8).
• Net impairment losses on financial assets (including recoveries) amounted to EUR 0.3 M (net recoveries of 0.1), equivalent to a loan loss level of 0.04 per cent (-0.00).
• Return on equity after taxes (ROE) decreased to 16.9 per cent (17.1).
• Earnings per share decreased by 4 per cent to EUR 0.82 (0.85).

Financial summary

Group	Q3 2026	Q2 2026	%	Q3 2025	%	Jan-Sep 2026	Jan-Sep 2025	%
EUR M
Income
Net interest income	23.0	23.9	-4	23.6	-3	70.2	71.5	-2
Net commission income	21.1	22.6	-7	20.1	5	66.2	62.7	6
IT income	8.3	8.9	-7	7.4	12	25.6	24.9	3
Other income	1.3	-2.5		0.8	51	1.5	4.8	-69
Total income	53.7	52.9	1	52.0	3	163.4	163.9	0
Staff costs	-23.2	-25.9	-10	-22.5	3	-73.9	-70.6	5
Other expenses	-11.0	-11.7	-5	-10.3	7	-34.1	-32.7	4
Depreciation/amortisation	-3.4	-3.2	5	-3.0	14	-9.9	-9.0	11
Total expenses	-37.7	-40.8	-8	-35.8	5	-117.9	-112.3	5
Profit before impairment losses	16.0	12.1	33	16.2	-1	45.6	51.6	-12
Impairment losses on financial assets, net	-0.3	0.6		0.1		0.0	-0.6
Net operating profit	15.8	12.7	24	16.3	-4	45.6	51.0	-11
Income taxes	-3.1	-3.0	4	-3.3	-4	-9.3	-9.4	-1
Profit for the period	12.6	9.6	31	13.1	-4	36.3	41.6	-13
Volume
Lending to the public	3,827	3,788	1	3,637	5
Deposits from the public	3,517	3,612	-3	3,681	-4
Actively managed assets	12,466	12,352	1	11,448	9
Managed mortgage loans	3,714	3,701	0	3,448	8
Equity capital	325	334	-3	339	-4
Balance sheet total	5,094	5,130	-1	5,003	2
Risk exposure amount	1,905	1,892	1	1,835	4

The Bank of Åland (Ålandsbanken) follows the disclosure procedure stipulated in “Disclosure obligation of the issuer (7/2013)”, published by the Finnish Financial Supervisory Authority and hereby publishes its Interim Report for the period January – September 2026, which is enclosed with this stock exchange release.

The Bank’s Interim Report for the period January – September 2026 is attached to this release in PDF format and is also available on the company’s web site at

https://assets.alandsbanken.com/pdf/result/en_resultat_jan-sep_26.pdf

Mariehamn, October 23, 2026

THE BOARD OF DIRECTORS

For more information please contact:

Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel. + 358 (0)40 512 7505

Attachment

• alandsbanken_en_resultat_jan-sep_26

AS Tallinna Vesi invites its shareholders, investors, analysts, and other stakeholders to join its investor conference webinar, introducing the results for the 3^rd quarter and 9 months of 2026.

The webinar is scheduled for 30 October 2026 at 11:00 am (EET) and will be held in English. The webinar will be hosted by Aleksandr Timofejev, Chief Executive Officer, and Taavi Gröön, Chief Financial Officer.

The questions will be answered by Aleksandr Timofejev and Taavi Gröön after the presentation. We encourage participants to send their questions before the webinar takes place, by 9:00 am (EET) on 30 October at the latest, to kommunikatsioon@tvesi.ee. Questions can also be asked during the webinar.

To join the webinar, please register via following link.

The registration will be open until 30 October at 9:00 am (EET). You will receive a link to the webinar.

The webinar will be recorded and made available online for everyone on the company’s website at www.tallinnavesi.ee and on AS Tallinna Vesi YouTube account.

Taavi Gröön
Chief Financial Officer
AS Tallinna Vesi
(372) 62 62 200
kommunikatsioon@tvesi.ee

Växjö, Sweden, 23 October 2026 * * * JLT Mobile Computers, a leading supplier of rugged computers for demanding environments, publishes its interim report for the period January–September 2026 today.

Summary of key figures

	July–Sept		January–Sept
Order Intake, MSEK	15.2 (30.1)		64.9 (111.6)
Net Sales, MSEK	16.9 (28.2)		75.1 (104.0)
Operating Profit, MSEK	-4.5 (1.6)		-5.9 (1.1)
Profit after taxes, MSEK	-4.6 (1.3)		-6.8 (0.9)
Cashflow, MSEK	2.5 (8.1)		-7.2 (2.9)

CEO comments

The period was characterized by weak demand, particularly in our largest segment, warehousing and logistics. This development was primarily attributable to component shortages and sharply higher prices, combined with geopolitical uncertainty and elevated energy costs. In some cases, memory prices increased by as much as 15 times as suppliers prioritized products for AI and server applications. As a result, JLT, like other industry participants, raised prices for its computers. This contributed to more cautious investment decisions and longer sales cycles. At the same time, our growth segments—container ports and construction and mining equipment—remained stable during the first nine months of the year despite the challenging market conditions.

During the quarter, order intake amounted to SEK 15.2 million and net sales to SEK 16.9 million, both significantly below the corresponding period of the prior year. The lower sales volume weighed on earnings, and operating loss amounted to SEK 4.5 million. For the first nine months of the year, order intake totaled SEK 64.9 million, net sales SEK 75.1 million, and operating loss SEK 5.9 million.

At the same time, the gross margin continued to demonstrate resilience. For the first nine months of the year, it was 41.5 percent, compared with 38.0 percent in the corresponding period of 2025. The improvement was primarily driven by a higher share of revenue from service agreements and a favorable currency effect from the stronger U.S. dollar. However, due to the lower sales volume, gross profit was insufficient to cover the cost base.

Cash flow was positive at SEK 2.5 million for the quarter but amounted to negative SEK 7.2 million for the first nine months of the year. At the end of the period, the Group had SEK 9.7 million in cash and cash equivalents, an equity ratio of 54 percent, and no interest-bearing debt. Our financial position provides flexibility, but developments during the year underscore the importance of continued cost and capital discipline.

Our priorities are clear: increase sales activity, expand our partner network, broaden the business into additional application areas, and align the cost base with the lower level of activity. Market uncertainty persists and sales cycles remain long, but the underlying need for reliable, rugged computers is unchanged, particularly in our target segments.

We are working with determination to improve near-term performance while strengthening our long-term position. A competitive product portfolio, a strong gross margin, and an experienced team provide a solid foundation. In the near term, our priorities are to strengthen order intake, protect cash flow, and align the cost base ahead of the fourth quarter and next year.

Per Holmberg, CEO

The full interim report is attached to this press release and available for download at the company’s website, jltmobile.com. Additional financial information is available online on JLT’s investor pages.

This information is information that JLT Mobile Computers AB (pub) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 08:00 am CET on Friday October 23, 2026.

Reader Enquiries JLT Mobile Computers Group	Certified Adviser
Per Holmberg, CEO	Eminova Fondkommission AB
Tel.: +46 70 361 3934	Tel.: +46 08 684 211 10
per.holmberg@jltmobile.com www.jltmobile.com	adviser@eminova.se www.eminova.se

About JLT Mobile Computers

JLT Mobile Computers is a leading supplier of rugged mobile computing devices and solutions for demanding environments. 30 years of development and manufacturing experience have enabled JLT to set the standard in rugged computing, combining outstanding product quality with expert service, support and solutions to ensure trouble-free business operations for customers in warehousing, transportation, manufacturing, mining, ports and agriculture. JLT operates globally from offices in Sweden, France, and the US, complemented by an extensive network of sales partners in local markets. The company was founded in 1994, and the share has been listed on the Nasdaq First North Growth Market stock exchange since 2002 under the symbol JLT. Eminova Fondkommission AB acts as Certified Adviser. Learn more at jltmobile.com.

Attachment

• Interim Report January–September, 2026

• EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses 
• Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial
• The data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings

COPENHAGEN, Denmark, October 23, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.

The data demonstrates EVX-01 inducing an immune response in all patients, with 89% of its personalised vaccine antigen targets inducing a tumor-specific immune response in treated patients. Further, sustained T-cell responses were observed, with preserved magnitude and breadth of the specific immune response, during the third year of the phase 2 trial in which EVX-01 was administered as monotherapy.

The new data also shows that all patients maintained their clinical response observed at two-year follow-up with no tumor progression observed through the third year of EVX-01 treatment alone. The data will be presented in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026 held in Madrid, Spain, tomorrow.

The new findings supplement the unprecedented two-year data presented at ESMO in 2025, showing a 75% Objective Response Rate with 25% of patients obtaining a complete response.

“We are delighted to announce yet another set of strong immune and clinical data for EVX-01. The 89% target precision documented in the trial is another confirmation that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and our platform as a validated technology for discovery and design of novel treatments,” says Birgitte Rønø, CSO and COO of Evaxion.

“What makes these three-year findings particularly compelling is not only the durability of clinical responses, but also the sustained strength and breadth of vaccine-induced T-cell immunity. These results offer an exciting glimpse into the future of precision oncology, where we can harness the unique biology of each patient’s tumor to train the immune system to recognize and target cancer with remarkable specificity. The prospect of translating this highly personalized immune response into long-lasting disease control represents an important step forward and offers renewed hope for patients facing advanced cancer“, says Professor Muhammad Adnan Khattak, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, Australia, key opinion leader and one of the trial’s investigators.

Building on convincing two-year results
In addition to promising response rates, the two-year data from the trial also showed a durable clinical benefit, with 92% of patients still responding at two years of follow-up and no relapses observed.

54% of patients had a deepened response following initiation of EVX-01 treatment, improving from stable disease or partial response to partial or complete response. Tumor reduction (target lesions) was observed in 15 out of the 16 patients enrolled in the trial.

EVX-01 induced an immune response in all patients, with 86% of the vaccine neoantigens generating potent specific T-cell responses as measured at the two-year follow-up. Analyses of additional samples collected during the one-year extension phase further increased this neoantigen hit-rate to 89%.

Evaxion maintains a cash runway extending well into the second half of 2027.

About the phase 2 trial
The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Six out of 12 responders continued in the trial’s one-year extension, where they received EVX-01 as stand-alone therapy.

Webinar on October 29, 2026
Evaxion will host a webinar featuring key opinion leader and trial investigator, Professor Muhammad Adnan Khattak, on October 29, 2026, at 15.30 CET/10.30am EDT.

The webinar can be attended through registration via this link.

In the webinar, Professor Khattak will present the three-year clinical and immune data from the EVX-01 phase 2 trial in patients with advanced melanoma. The presentation will highlight clinical outcomes, durability of responses and vaccine-induced immune responses following three years of follow-up. The presentation will be followed by a Q&A session, with participants encouraged to submit questions.

Poster presentation details

• Poster title: EVX-01, a personalized cancer vaccine, induces sustained T-cell responses and durable disease control in advanced melanoma after three-year of follow-up
• Presentation#: 2006P
• Location: Poster Area – Hall 5
• Topic: Investigational immunotherapy
• Date/Time: October 24, 2026, at 12:00 – 12:45 CET
• Presenter: Professor Muhammad Adnan Khattak, Director, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, WA, Australia

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.